Shares of Palatin Technologies Inc. PTN, +4.69% rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on
, +4.06% treatment for hypoactive sexual desire disorder triggered a $60 million milestone payment. Trading volume was over 2.9 million shares, making Palatin's stock the most actively traded ahead of the open. The FDA granted marketing approval for 's stock surged 8.1% ahead of the open. The company expects to receive the milestone payment in July. Based on the license agreement with
BringeReprobate
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: MarketWatch - 🏆 3. / 97 続きを読む »